FDA approves cancer-fighting heavy-duty therapy Imbruvica in combination with obinutuzumab for CLL/SLL patients

today, Janssen and AbbViecompany(http://announced that the U.SFDA http://
approved the anti-cancer heavy-duty therapy Imbruvica (ibrutinib, ) and obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia/small lymphoma (CLL/CLL) who have not been treatedabout Imbruvica
Imbruvica is an oral Bruton's tyrosine kinase (BTK) inhibitorSpecific tumor cells rely on the BTK signaling pathway to promote cell proliferation and metastasisBy blocking the BTK signaling pathway, Imbruvica can help drive abnormal B cells out of the environment (lymph nodes, bone marrow, etc.) that support their growthImbruvica has been approved for treatment for six diseases, including five blood cancersthe studythis approval is based on the performance of the combination therapy in a phase 3 clinicaltrial(http://called iLLUMINATE At a median follow-up time of 31 months, the combination of Imbruvica plusobinutuzumab significantly improved progression less than the combination of benzoic acid nitrogen mustard (chemotherapy
drug (http:// ) plus obinutuzumab, reducing the risk of disease progression or death by 77% 　　The PFS in the Imbruvica gaobinutuzumab combination group has not yet reached, and the active control group HAS PFS for 19 months (HR: 0.23; 95% CI: 0.15-0.37; p 0001 for high-risk patients (carrying 17p missing/TP53 gene mutations, 11q missing, or unmutated IGHV genes), this combination therapy was more effective and reduced the risk of disease progression and death by 85% compared to the control group The overall remission rate in the Imbruvica plusobinutuzumab group was 89 per cent, better than the 73 per cent in the active control group, according to the Independent Review Committee (IRC)